Follow-up of non-responders was not possible. Students developed the questionnaire using two previously validated tools assessing satisfaction with information provision (SIMS) and adherence (Morisky)2. The questionnaire selleck screening library also contained demographic questions together with a request for the participant to state whether they had received an advanced service e.g. MUR or NMS. The questionnaire was piloted on 20 participants in one pharmacy and found to be suitable. 400 questionnaires were distributed across four pharmacies. 265 (66.3%) questionnaires were returned to the university. On inspection, 26 questionnaires were excluded as participants identified themselves as receiving only one medicine. Mean (SD)
age was 65.5 Vorinostat clinical trial (14.2) years and 123 (53%) of the sample were female. Of the 231 and 228 who responded
to the question, 105 (45.5%) had experienced an MUR and 51 (22.4%) had experienced the NMS, respectively. Table one illustrates the relationship between advanced service provision and both satisfaction and adherence. If patients are adherent to therapy they also have a significantly higher information satisfaction score (p = 0.004; MWU). Table 1: The impact of advanced service provision on medicines information and adherence Experienced an advanced service (self-report) p-value Yes No *Fisher’s exact (n = 211); **Mann-Whitney U (n = 194) This evaluation of current community pharmacy advanced service provision has demonstrated that patients who have experienced an MUR or the NMS report higher satisfaction with information about medicines and greater adherence to therapy than those who have not. Limitations include the small number of pharmacies in which Ureohydrolase this was performed and the selection bias of the pharmacies recruited. Pharmacy staff were asked to approach consecutive patients but there is no method of determining if this was the case. Furthered
evaluation is warranted with a larger number of pharmacies across the UK. 1. WHO. Adherence to long-term therapies. Evidence for Action. (World Health Organisation, Geneva, 2003). 2. Morisky, D., Green, L. & Levine, D. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24: 67–74. Rachna Patel1, Jignesh Patel1,2, Rosalind Byrne2, Graham Davies1 1King’s College London, London, UK, 2King’s College Hospital, London, UK Many complementary and alternative medicine (CAM) therapies are reported to interact with warfarin. A significant number of patients established on warfarin therapy were consuming CAM known to interact with warfarin. There is limited awareness amongst patients for the potential for CAM-warfarin interactions. It is important that healthcare professionals routinely ask patients about CAM use and ensure patients are made aware of the potential for interactions. Whilst most CAM therapies are considered innocuous, there is the potential for CAM-drug interactions to occur with anticoagulant therapy, both from a pharmacokinetic (St.